An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin With/Without OADs in Type 2 Diabetes (BEGIN™: BB)

Trial Profile

An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin With/Without OADs in Type 2 Diabetes (BEGIN™: BB)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Acronyms BEGIN:BB
  • Sponsors Novo Nordisk
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top